By Susan M. Brackney | Fall 2018
Photography by Anna Powell Denton
Last year was a peak year for drug overdoses in southern Indiana — particularly along Bloomington's iconic Kirkwood Avenue. “It was the worst year I've seen in my 31-year career in the police department,” recalls Bloomington Police Department Chief Michael Diekhoff (B.A. ’89, Criminal Justice). While those overdoses weren't solely the result of opioid use, dependence on the painkillers has become increasingly common.
What's happening in Monroe County mirrors a larger trend. A 2016 IUPUI report suggests that, since 1999, Indiana's rate of fatal drug overdoses has increased by 500 percent. Put another way, overdose deaths now supersede automobile accident fatalities. What's more, Hoosier deaths from opioid use were up by 111 percent between 2015 and 2016, according to State of Indiana Management Performance Hub statistical reports. And deaths due to synthetic opioids were up by 134 percent within the same period.
The scope and urgency of the problem call for a response that's both sweeping and concerted. Enter IU's “Responding to the Addictions Crisis” Grand Challenge initiative — and College of Arts and Sciences researchers singularly positioned to make a difference.
“We have the scientists who work on studying addictions all the way from the molecular level to the social-psychological level,” College of Arts and Sciences Executive Dean Larry Singell says. “If you look at the Department of Psychological and Brain Sciences, which is likely to be a major contributor to the grand challenge, they have faculty who look at models of addiction, how it works and what its impact is, and how you can address it at the cellular level.”
Opioid alternatives
Andrea Hohmann is a Linda and Jack Gill Chair of Neuroscience and a professor in the Department of Psychological and Brain Sciences. “With the current opioid epidemic," she says, "it's really become clear that there's an urgent need to find better treatments for chronic pain that are non-addicting and that are safe and effective.”
To that end, Hohmann and her colleagues have picked up where others have left off by testing new therapeutic indications for existing molecules. Hohmann and her team recently reported on such a drug, and her lab showed that this compound “was able to fully reverse established neuropathic pain in mice. Moreover, when we gave the drug repeatedly to animals, we did not see the development of tolerance,” Hohmann explains.